Health
Patients with tuberculosis (TB), including children and those with drug-resistant forms, can now complete treatment in a shorter, fully oral course under new international guidelines.
Health
The recommendations, developed by leading international respiratory and infectious disease bodies, replace traditional six-month therapies with simpler and more effective regimens.
Health
Developed using rigorous evidence-based frameworks called GRADE and GRADE-ADOLOPMENT, the guidelines draw on large clinical trial data and systematic reviews.
Health
For people with drug-susceptible pulmonary TB, a new four-month regimen is now advised, replacing the six-month course.
Health
Adults with drug-susceptible TB are recommended a combination of isoniazid, rifapentine, pyrazinamide, and moxifloxacin.
Health
Children begin with an eight-week intensive phase using isoniazid, rifampin, pyrazinamide, and sometimes ethambutol, followed by a continuation phase with isoniazid and rifampin.
Health
For drug-resistant TB, the guidelines emphasise new combinations built around bedaquiline, pretomanid, and linezolid.